Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 amp |
| Therapy | Nivolumab |
| Indication/Tumor Type | basal cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 amp | basal cell carcinoma | predicted - sensitive | Nivolumab | Case Reports/Case Series | Actionable | In a clinical case study, a patient with metastatic basal cell carcinoma harboring CD274 amplification and a high mutational burden was sensitive to treatment with Opdivo (nivolumab), demonstrating reduced lesion size after two months of treatment and a nearly complete regression of liver lesions after four months of treatment (PMID: 27942391). | 27942391 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (27942391) | Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. | Full reference... |